AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly
non-squamous adenocarcinoma non-small cell lung cancer
Exclusion Criteria:
- Contraindications to Avastin treatment according to the Summary of Product
Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
Outcome Time Frame:
approximately 4.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: BfArm (Federal Institute for Drugs and Medical Devices)
Study ID:
ML28306
NCT ID:
NCT01827852
Start Date:
February 2013
Completion Date:
October 2017
Related Keywords:
- Non-Small Cell Lung Cancer
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
